Skip to main content
Oncoinvent ASA logo

Oncoinvent ASA — Investor Relations & Filings

Ticker · OCIN ISIN · NO0010779341 LEI · 54930076H5GUZRMSNR39 Euronext Growth Manufacturing
Open in API
Filings indexed 138 across all filing types
Latest filing 2025-10-29 Report Publication Anno…
Country NO Norway
Listing Euronext Growth OCIN

About Oncoinvent ASA

https://www.oncoinvent.com/

Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies for cancer. The company's core focus is on direct alpha therapy, a technology platform designed to deliver potent, short-range radiation directly to cancerous tumors. Its lead product candidate, Radspherin®, is composed of inorganic microparticles that carry the alpha-emitting radionuclide Radium-224. This formulation is engineered for regional retention and slow degradation, enabling a high radiation dose to be administered within the peritoneal cavity while minimizing systemic exposure. Oncoinvent's clinical programs are primarily investigating the use of Radspherin® for treating metastatic cancers in the peritoneal cavity, including ovarian and colorectal cancer.

Recent filings

Filing Released Lang Actions
Financial calendar
Report Publication Announcement Classification · 100% confidence The document is a 'Financial calendar' listing future dates for the publication of annual reports, quarterly reports, and the Annual General Meeting. It does not contain financial results or meeting materials itself, but rather serves as a schedule announcement. Since it is a short notice regarding the timing of future report releases, it fits the definition of a Report Publication Announcement (RPA).
2025-10-29 English
Merger of BerGenBio and Oncoinvent completed - Attachment: 2025_10_29_merger_completed.pdf
M&A Activity Classification · 100% confidence The document announces the formal completion of a merger between BerGenBio ASA and Oncoinvent ASA, including the registration of the merger, the dissolution of the target company, the issuance of merger consideration shares, and the resulting change in share capital. This falls squarely under M&A activity (takeover/merger completion).
2025-10-29 English
Merger of BerGenBio and Oncoinvent completed
M&A Activity Classification · 100% confidence The document announces the formal completion of a statutory triangular merger between BerGenBio ASA and Oncoinvent ASA. It details the registration of the merger, the dissolution of one entity, the name change of the combined company, and the issuance of merger consideration shares. Since the document focuses on the finalization of a merger transaction, it falls under M&A Activity.
2025-10-29 English
Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies -
Regulatory Filings Classification · 100% confidence The document is a press release issued by Oncoinvent ASA announcing the presentation of clinical trial results (Phase 1/2a for Radspherin) at a medical congress. It provides highlights of the trial data, company background, and forward-looking statements. It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement. As it is a general corporate announcement regarding clinical progress, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-10-29 English
Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies
Regulatory Filings Classification · 100% confidence The document is a press release issued by Oncoinvent ASA announcing the presentation of clinical trial results (Phase 1/2a for Radspherin) at a medical congress. It does not fit into financial reporting categories like 10-K or IR, nor is it a regulatory filing or a report publication announcement. Since it is a corporate announcement regarding clinical progress and research findings, it falls under the general regulatory/corporate announcement category.
2025-10-29 English
BerGenBio and Oncoinvent - Last day of trading in the shares of Oncoinvent - Attachment: 2025_10_28_last_day_of_trading.pdf
Delisting Announcement Classification · 100% confidence The document is a short announcement regarding the last day of trading for Oncoinvent shares due to a merger with BerGenBio. It does not contain the full merger agreement or financial statements, but rather serves as a notice of a corporate event (delisting/merger completion). Since it specifically addresses the cessation of trading on an exchange, it fits the criteria for a delisting announcement.
2025-10-29 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.